Oruka Therapeutics (NASDAQ:ORKA) Shares Up 9.5% – Here’s Why

Posted by Brian Himes on Jun 4th, 2026

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) shot up 9.5% on Thursday . The company traded as high as $61.88 and last traded at $62.6320. 376,265 shares changed hands during trading, a decline of 64% from the average session volume of 1,055,575 shares. The stock had previously closed at $57.20.

Analyst Ratings Changes

ORKA has been the subject of a number of research analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a research note on Tuesday. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 16th. UBS Group lifted their price target on Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. BTIG Research reissued a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, May 14th. Finally, Barclays upped their price target on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, April 27th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.30.

Check Out Our Latest Analysis on Oruka Therapeutics

Oruka Therapeutics Price Performance

The company has a market cap of $3.83 billion, a price-to-earnings ratio of -32.58 and a beta of -0.26. The firm’s 50 day simple moving average is $60.66 and its 200-day simple moving average is $42.22.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, analysts forecast that Oruka Therapeutics, Inc. will post -2.05 EPS for the current year.

Insider Buying and Selling

In other news, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the transaction, the chief executive officer owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $59.07, for a total value of $607,830.30. Following the completion of the sale, the senior vice president directly owned 16,406 shares in the company, valued at $969,102.42. This represents a 38.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 139,055 shares of company stock worth $8,095,785. 23.49% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently bought and sold shares of the stock. Fairmount Funds Management LLC grew its holdings in Oruka Therapeutics by 9.9% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after buying an additional 333,340 shares during the last quarter. Secure Asset Management LLC purchased a new position in Oruka Therapeutics during the fourth quarter worth approximately $2,475,000. Avoro Capital Advisors LLC acquired a new stake in Oruka Therapeutics during the 3rd quarter worth approximately $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in shares of Oruka Therapeutics in the third quarter worth about $296,000. Finally, Commodore Capital LP boosted its position in shares of Oruka Therapeutics by 23.5% in the third quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock worth $33,711,000 after buying an additional 333,340 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.